August 10, 2021
Bayer Yakuhin on August 6 rolled out the oral solution version of its tropomyosin receptor kinase (TRK) inhibitor Vitrakvi (larotrectinib) in Japan for the treatment of neurotrophic TRK fusion-positive advanced or relapsed solid tumors. The company developed the oral solution...read more